Skip to main content

Apotex Inc., the largest Canadian generic drug company, is taking over a generic drug maker in Belgium for an undisclosed price.

Privately held Apotex said Thursday that Topgen ESV, being acquired from Zambon Group SpA of Italy, "represents an important milestone for Apotex International as it extends the organization's footprint in Europe and will be a launching pad for many EU products currently in the Apotex development pipeline."

Topgen, headquartered in Brussels, has about 30 generic registrations and a sales force covering Belgium.

Story continues below advertisement

Apotex, which has 6,800 employees and worldwide sales of more than $1-billion, said the Belgian generic sector is relatively undeveloped, with about 10 per cent of the overall drug market, "but it continues to experience strong growth."

Zambon said the divestment of Topgen advances its strategy of focusing on branded products, "while simultaneously strengthening our relationship with Apotex, which is already a partner of Zambon and Chiesi [Farmaceutici SpA]in Italy."



Report an error
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter